Kinnear Pharmaceuticals

FDA QiDP designation is a significant milestone PARK CITY, UTAH, UNITED STATES, July 31, 2023/EINPresswire.com/ — Kinnear Pharmaceuticals, LLC, a subsidiary of

New Publication regarding Ceragenin CSA-131’s Potent Efficacy against fungal pathogen Candida auris, a New Serious Global Health Threat

Colistin is the last agent used to combat bacteria that are resistant to the strongest antibiotics. Colistin has remained the best tool

A recent published study by Professor Jordi Vila and his colleagues at the University of Barcelona, Spain has found that CSA-131 is